Medigene AG. (8/3/16). "Press Release: Medigene Participates at Five Upcoming International Conferences". Martinsried.

	Organisation	Medigene AG (FSE: MDG1, Prime Standard)
	Group	Medigene (Group)
	Organisation 2	BIO Deutschland e. V.
	Product	Baader Investment Conference 2016 Munich
	Product 2	European Business Development Conference 2016 Frankfurt (Offenbach) (EBDC 2016)
	Index term	Medigene–Baader Bank: investor conference, 201609 supply service Medigene presents at Baader Investment Conference 2016 in Munich
	Index term 2	Medigene–BIO Deutschland: partnering conference, 201609 supply service Medigene participates in EBDC 2016 in Frankfurt
	Person	Schendel, Dolores J. (Medigene 201602– CEO before CMO before Trianta Immunotherapies + HelmholtzZentrum München)
	Person 2	Hofmann, Julia (MC Services 201910– before Medigene)

Medigene AG (MDG1, Frankfurt, Prime Standard) announces its participation at five upcoming science, investment and business development conferences:

CAR-TCR Summit

Date: 13 - 15 September 2016
Location: Boston, USA
CEO/CSO Prof. Dolores Schendel will give a talk on 14 September on the topic: "The ABC's of Adoptive T Cell Therapy Using Optimal-Affinity Natural TCRs Specific for Hematological Malignancies and Solid Tumors".

Baader Investment Conference

Date: 20 - 22 September 2016
Location: Munich, Germany
Medigene's Senior Vice President Corporate Development, Dr. Dr. Olav Zilian, will give a corporate presentation on 21 September.

Phacilitate Leaders Europe

Date: 21 - 22 September 2016
Location: Berlin, Germany
Medigene's Senior Vice President Medical Affairs & CMO, Dr. Kai Pinkernell, will present on 22 September 2016 on: "What improvements can second and third generation CAR and TCR-based immunotherapies offer in terms of both safety and persistence of response?"

Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival

Date: 25 - 28 September 2016
Location: New York, USA
Medigene will present a poster on 25 and 26 September with the title: "Method for molecular characterization of antigens, epitopes and T cell receptors for adoptive CD4 immunotherapy".

European Business Development Conference

Date: 27 - 28 September 2016
Location: Frankfurt, Germany

Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. Medigene concentrates on the development of personalized T cell-based immunotherapies.

For more information, please visit www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Contact Medigene AG

Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01,
email: investor@medigene.com

Record changed: 2017-07-02